Current NHS consultant posts held
Consultant Medical Oncologist West Suffolk Hospital
Research interests
Use of targeted therapies in lung & GI cancer
Phase II/III studies
Cancer unknown primary
Personal interests
Football, cricket, tennis
Reading
Music
Awards received
ASCO merit award 2008
Publications
Lightowlers S & Patterson D. Mismanagment of malignant hypercalcaemia (2013). Clin Med February 1, 2013 vol. 13 no. 1 118
Patterson D.M, Zweifel M, Middleton MR, Price PM, Folkes LK, Stratford MR, Ross P, Halford S, Peters J, Balkissoon J, Chaplin DJ, Padhani AR, Rustin GJ (2012): Phase I clinical and pharmacokinetic evaluation of the vascular-disrupting agent OXi4503 in patients with advanced solid tumors. Clin Cancer Res. 2012 Mar 1;18(5):1415-25.
.
Patterson D. M, Aries J, Hyare H, Holder D, Rees, J and SM Lee (2011). Non-convulsive status epilepticus and leucoencephalopathy following high-dose methotrexate. J Clin Oncol. 2011 Jun 1;29(16):e459-61
Patterson D. M. and S. M. Lee (2010). Glucarpidase following high-dose methotrexate: update on development. Expert Opinion on Biological Therapy 10(1): 105-111
Whelan J, Patterson D. M, Perisoglou M, Bielack S, Marina N, Smeland S, Bernstein M (2010). The role of interferons in the treatment of osteosarcoma. Pediatr Blood Cancer. 54(3):350-4
Patterson, D. M., A. R. Padhani, et al. (2008). "Technology insight: water diffusion MRI--a potential new biomarker of response to cancer therapy." Nat Clin Pract Oncol 5(4): 220-33.
Patterson, D. M., N. Murugaesu, et al. (2008). "A review of the close surveillance policy for stage I female germ cell tumors of the ovary and other sites." International Journal of Gynecological Cancer 18(1): 43-50.
Patterson, D. M. and G. J. Rustin (2007). "Vascular Damaging Agents." Clin Oncol (R Coll Radiol) 19(6): 443-56.